Calmpent

Calmpent

gabapentin

Manufacturer:

Lloyd

Distributor:

Pharma 3
Full Prescribing Info
Contents
Gabapentin.
Action
Pharmacotherapeutic Group: Anticonvulsant.
Pharmacology: Pharmacokinetics: Gabapentin is absorbed from the GIT by means of saturable mechanism. Following multiple dosing, peak plasma concentrations are usually achieved within 2 hrs of administration and steady-state achieved within 1-2 days. Gabapentin is not appreciably metabolized and most of the dose is excreted unchanged in the urine with the remainder appearing in the feces. Gabapentin is widely distributed throughout the body but binding to plasma proteins is minimal. The elimination t½ has been reported to be about 5-7 hrs. Gabapentin is distributed into breastmilk.
Indications/Uses
Treatment of partial seizures with or without secondary generalization and is used as adjunctive therapy in patients with or without secondary generalization and is used as adjunctive therapy in patients unresponsive to or intolerant to standard anticonvulsant drug. Calmpent is not generally considered to be effective for absence seizures. It is also used in the treatment of neuropathic pain.
Dosage/Direction for Use
The initial dose is 300 mg by mouth on the 1st day of treatment, 300 mg twice daily on the 2nd day, and 300 mg 3 times daily on the 3rd day. Thereafter the dose may be increased in increments of 300 mg daily until effective anticonvulsants control is achieved, which is usually within the range of 0.9-1.2 g daily. Higher doses up to a maximum of 2.4 g daily may be required in some patients. Doses up to 3.6 g daily administered for a short period have been reported to be well tolerated. The total daily dose should be taken in 3 equally divided doses and the maximum dosage interval should not exceed 12 hrs.
Special Precautions
Gabapentin should be used with caution in patients with a history of psychotic illness, renal impairment, dosage reduction in patients with reduced renal function or those undergoing hemodialysis. False-positive readings have been reported with some urinary protein tests in patients taking gabapentin. Breastfeeding, carcinogenicity, driving, effects on mental state, pregnancy. Care is required when withdrawing gabapentin therapy.
Use In Pregnancy & Lactation
Use with caution when breastfeeding and during pregnancy.
Adverse Reactions
Somnolence, dizziness, ataxia, fatigue, nystagmus, tremor, diplopia, ambylopia, pharyngitis, dysarthria, weight gain, dyspepsia, amnesia, weakness, paresthesia, arthralgia, purpura, leucopenia, anxiety and UTI. Rarely, pancreatitis, altered liver function tests, erythema multiforme, Stevens-Johnson syndrome, rhinitis, nervousness, myalgia, headache, nausea and vomiting, and blood glucose fluctuations in diabetes.
Drug Interactions
The absorption of gabapentin from the GIT is reduced by antacids and concomitant administration is therefore not recommended. Cimetidine has been reported to reduce the renal clearance of gabapentin but are not considered to be of clinical importance.
Storage
Store at temperatures not exceeding 25°C. Protect from light.
MIMS Class
ATC Classification
N03AX12 - gabapentin ; Belongs to the class of other antiepileptics.
Presentation/Packing
Cap 300 mg x 100's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in